The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
Richard John BryantJon D OxleyGrace J YoungJanet A LaneChris MetcalfeMichael DavisEmma L TurnerRichard M MartinJohn R GoepelMurali VarmaDavid F GriffithsKen GrigorNick MayerAnne Y WarrenSelina BhattaraiJohn DormerMalcolm MasonJohn StaffurthEleanor WalshDerek J RosarioJames W F CattoDavid E NealJenny L DonovanFreddie C Hamdynull nullPublished in: BJU international (2020)
We demonstrate that one-third of the ProtecT cohort consists of people with intermediate-/high-risk disease, and the outcomes data at an average of 10 years' follow-up are generalizable beyond men with low-risk PCa.